-
公开(公告)号：US20180298076A1
公开(公告)日：2018-10-18
申请号：US15745483
申请日：2016-07-22
发明人： Elizabeth M. Murphy Topp , Hamed Tabatabaei Ghomi , Markus Lill , Shenbaga Moorthy Balakrishnan
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation.
-
公开(公告)号：US10954283B2
公开(公告)日：2021-03-23
申请号：US16278851
申请日：2019-02-19
发明人： Elizabeth M. Murphy Topp , Hamed Tabatabaei Ghomi , Markus Lill , Shenbaga Moorthy Balakrishnan
IPC分类号： A61K38/26 , A61K47/52 , C07K14/605 , A61K38/00
摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.
-
公开(公告)号：US20190202884A1
公开(公告)日：2019-07-04
申请号：US16278851
申请日：2019-02-19
发明人： Elizabeth M. Murphy Topp , Hamed Tabatabaei Ghomi , Markus Lill , Shenbaga Moorthy Balakrishnan
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , A61K38/26 , A61K47/52
摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation.
-
公开(公告)号：US11472857B2
公开(公告)日：2022-10-18
申请号：US17177799
申请日：2021-02-17
发明人： Elizabeth M. Murphy Topp , Hamed Tabatabaei Ghomi , Markus Lill , Shenbaga Moorthy Balakrishnan
IPC分类号： A61K38/26 , A61K47/52 , C07K14/605 , A61K38/00
摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.
-
公开(公告)号：US20210155614A1
公开(公告)日：2021-05-27
申请号：US17165136
申请日：2021-02-02
发明人： Richard M. Van Rijn , Mark S. Cushman , Markus Lill , Robert J. Cassell , Amr Hamed Mahmoud Abdallah , Mohamed S.A. Elsayed
IPC分类号： C07D409/12 , A61P25/32 , C07D405/12 , C07D417/12
摘要： The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel δ-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
-
公开(公告)号：US11787787B2
公开(公告)日：2023-10-17
申请号：US17165136
申请日：2021-02-02
发明人： Richard M Van Rijn , Mark S Cushman , Markus Lill , Robert J Cassell , Amr Hamed Mahmoud Abdallah , Mohamed S. A. Elsayed
IPC分类号： C07D409/12 , A61P25/32 , C07D405/12 , C07D417/12
CPC分类号： C07D409/12 , A61P25/32 , C07D405/12 , C07D417/12
摘要： The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel δ-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
-
公开(公告)号：US20210300982A1
公开(公告)日：2021-09-30
申请号：US17177799
申请日：2021-02-17
发明人： Elizabeth M. Murphy Topp , Hamed Tabatabaei Ghomi , Markus Lill , Shenbaga Moorthy Balakrishnan
IPC分类号： C07K14/605 , A61K38/26 , A61K47/52
摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.
-
公开(公告)号：US10954224B2
公开(公告)日：2021-03-23
申请号：US16620907
申请日：2018-06-08
发明人： Richard M Van Rijn , Mark S Cushman , Markus Lill , Robert J Cassell , Amr Hamed Mahmoud Abdallah , Mohamed S. A. Elsayed
IPC分类号： C07D409/12 , A61P25/32 , C07D405/12 , C07D417/12
摘要： The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel δ-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
-
公开(公告)号：US10308701B2
公开(公告)日：2019-06-04
申请号：US15745483
申请日：2016-07-22
发明人： Elizabeth M. Murphy Topp , Hamed Tabatabaei Ghomi , Markus Lill , Shenbaga Moorthy Balakrishnan
IPC分类号： A61K38/26 , C07K14/605 , A61K47/52 , A61K38/00
摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids, e.g., phosphorylation and/or sulfation, to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.017 秒)
